Vol. 5 (04) pp. 489-499 DOI: 10.21474/IJAR01/3837

EXPRESSION OF MIDKINE AND KI-67 PROTEINS IN AMELOBLASTOMA VERSUS AMELOBLASTIC CARCINOMA ACCORDING TO THEIR CLINICOPATHOLOGIC PARAMETERS.

, , and
  • Dentist at Assuit University Hospital, Assuit, Egypt.
  • Associate Professor of Oral and Maxillofacial Pathology, Faculty of Dentistry, Minia University, Minia, Egypt.
  • Professor of Pathology, Faculty of Medicine, Assuit University, Assuit, Egypt
  • Lecturer of Oral and Maxillofacial Pathology, Faculty of Dentistry, Minia University, Minia, Egypt.
20 Downloads 163 Views
Crossref

Download Full Paper (PDF)

Abstract

Aims: To correlate between Midkine and Ki-67 expression in ameloblastoma and ameloblastic carcinoma and their relation to clinicopathological parameters. Methods: This study was carried out on 27 cases of ameloblastoma and ameloblastic carcinoma. Archival blocks were obtained from Pathology Department, Faculty of Medicine, Assuit University. Paraffin sections of tumor tissue from all cases were submitted for routine haematoxylin and eosin stain and immunohistochemistry using Midkine and Ki-67 monoclonal antibodies. Immunostaining was evaluated using area fraction and the results were analyzed statistically. P value ≤ 0.05 was considered significant. Result: Among 27 cases, 11 were females and 16 were males with ratio 1:1.4. Age ranged from 12 to 64 years old with a mean age 34.2 years. Ten lesions were located in maxilla and 17 were located in mandible with ratio 1: 1.7. No statistically significant in midkine or Ki-67 expression was found in relation to patient age, gender or tumor site. However, there was a significant difference in their expression between ameloblastoma and ameloblastic carcinoma. Moreover, There was a significant positive correlation between midkine and Ki-67 expression in the studied cases (p = 0.000). Conclusion: Evaluation of Midkine and Ki-67 expression can provide information about clinical behavior of the tumor. There is a significant positive correlation between midkine and Ki-67 expression in ameloblastoma and it is not dependent on clinical or tumor criteria.

Keywords

How to Cite This Article

Fatma Abdelghani Abdelhamed, Amr Helmy El-Bolok, Howayda Ismaeel Hassan and Enas Alaa Eldin Abd El-Aziz. (2017); EXPRESSION OF MIDKINE AND KI-67 PROTEINS IN AMELOBLASTOMA VERSUS AMELOBLASTIC CARCINOMA ACCORDING TO THEIR CLINICOPATHOLOGIC PARAMETERS., International Journal of Advanced Research (IJAR), 5 (04), 489-499, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/3837

Corresponding Author

Fatma Abdelghani Abdelhamed
Dentist at Assuit University Hospital, Assuit, Egypt

Article Analytics

References

  1. Abdel-Aziz A. & Amin M. M. (2012). EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence. Diagnostic Pathology, 7(1), article
  2. Amaral F. R., Mateus G. C., Bonisson L. A., de Andrade B. A., Mesquita R. A., Horta M. C. & Marigo Hde A. (2012). Cell proliferation and apoptosis in ameloblastomas and keratocystic odontogenic tumors. Brazilian Dental Journal, 23(2), 91-96.
  3. Barnes L., Eveson J. W., Reichart P. & Sidransky D. (2005). World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours (D. G. Gardner, K. Heikinheimo, M. Shear, H. P. Philipsen & H. Coleman Eds.). Lyon: IARC Press, 287-293.
  4. Bologna-Molina R., Mosqueda-Taylor A., Molina-Frechero N., Mori-Estevez A. D. & Sanchez-Acuna G. (2013). Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Medicina Oral Patolog?a Oral y Cirugia Bucal, 18(2), e174-e179.
  5. Carreon-Burciaga R. G., Gonzalez-Gonzalez R., Molina-Frechero N. & Bologna-Molina R. (2015). Immunoexpression of Ki-67, MCM2 and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns. Disease Markers,
  6. Florescu A., Simionescu C., Ciurea R. & Pitru A. (2012). P53, Bcl-2 and Ki67 immunoexpression in follicular solid ameloblastomas. Romanian Journal of Morphology and Embryology, 53(1), 105-109.
  7. Fujita S., Seki S., Fujiwara M. & Ikeda T. (2008). Midkine expression correlating with growth activity and tooth morphogenesis in odontogenic tumors. Human Pathology, 39(5), 694-700.
  8. Gadbail A. R., Patil R. & Chaudhary M. (2012). Co-expression of Ki-67 and p53 protein in ameloblastoma and keratocystic odontogenic tumor. Acta Odontologica Scandinavica, 70(6), 529-535.
  9. Hodeib H., Elshora O., Selim A., Sabry N. M. & El-Ashry H. M. (2017). Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electron Physician, 9(1), 3492-3498.
  10. Ikematsu S., Yano A., Aridome K., Kikuchi M., Kumai H., Nagano H., Okamoto K., Oda M., Sakuma S., Aikou T., Muramatsu H., Kadomatsu K. & Muramatsu T. (2000). Serum midkine levels are increased in patients with various types of carcinomas. British Journal of Cancer, 83(6), 701?706.
  11. Intapa C. (2017). Analysis of Prevalence and Clinical Features of Ameloblastoma and its Histopathological Subtypes in Southeast Myanmar and Lower Northern Thailand Populations: A 13-Year Retrospective Study. J Clin Diagn Res, 11(1), ZC102-ZC106.
  12. Jono H. & Ando Y. (2010). Midkine: a novel prognostic biomarker for cancer. Cancers, 2(2), 624-641.
  13. Kadomatsu K. & Muramatsu T. (2004). Midkine and pleiotrophin in neural development and cancer. Cancer Letters, 204(2), 127-143.
  14. Kadomatsu K. (2005). The Medkine Family in Cancer, Inflammation and Neural Development. Nagoya Journal of Medical Science, 67, 71-82.
  15. Meer S., Galpin J. S., Altini M., Coleman H. & Ali H. (2003). Proliferating cell nuclear antigen and Ki67 immunoreactivity in ameloblastomas. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 95(2), 213-221.
  16. Muramatsu H. & Takahashi M. (1991). Purifation of recombinant Midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochemical and Biophysical Research Communications, 177(2), 652-658.
  17. Niranjan K. C. & Shaikh Z. (2014). Clinicopathological correlation of odontogenic cysts and tumours in a South Indian population over a 20-year period. International Journal of Dental Research, 2(2), 32-36.
  18. Sandra F., Harada H., Nakamura N. & Ohishi M. (2004). Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncology, 40(3), 274-280.
  19. Sandra F., Mitsuyasu T., Nakamura N., Shiratsuchi Y. & Ohishi M. (2001). Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncology, 37(2), 193-198.
  20. Scheper M. A., Duarte E. C., Intapa C., Zhang M., Nascimento L. M., Almeida T. P., Gomes A. C., Song S., Chaisuparat R., Batista A. C. & Jham B. C. (2012). Expression of midkine in ameloblastomas and its correlation with clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol, 114(4), 497-502.
  21. Shaikhi K., Neiders M., Chen F. & Aguirre A. (2012). Morphological Variants of Ameloblastoma and Their Mimickers. North American Journal of Medicine and Science, 5(1), 20-28.
  22. Yoon H. J., Jo B. C., Shin W. J., Cho Y. A., Lee J. I., Hong S. P. & Hong S. D. (2011). Comparative immunohistochemical study of ameloblastoma and ameloblastic carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 112(6), 767-776.

Similar Articles

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.